What Schrodinger, Inc. does.

Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.

Traditional drug discovery and development efforts are complex, lengthy and capital-intensive, and are prone to high failure rates. Traditional drug discovery relies upon many iterations of costly and time-consuming manual molecule design, chemical synthesis, and experimental testing. One of the primary reasons for long timelines, high costs, and high failure rates in drug discovery is that predicting properties of molecules in advance of chemical synthesis is extremely complex and not amenable to traditional approaches.

Revenue and profit, by fiscal year.

More on SDGR.

• Schrodinger, Inc. summary
• Schrodinger, Inc. financial statements
• Schrodinger, Inc. key metrics
• Schrodinger, Inc. health scores and style box
• Schrodinger, Inc. earnings
• Schrodinger, Inc. dividends
• Schrodinger, Inc. valuation
• Schrodinger, Inc. ownership and insiders
• Schrodinger, Inc. peers

Figures from Schrodinger, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.